Int J Antimicrob Agents Tocilizumab Administration in a Refractory Case of COVID-19

[tetano]

Int J Antimicrob Agents


. 2020 Jun 2;106043.
doi: 10.1016/j.ijantimicag.2020.106043. Online ahead of print.
Tocilizumab Administration in a Refractory Case of COVID-19


Farzaneh Dastan ¹ , Seyed Alireza Nadji ² , Ali Saffaei ³ , Payam Tabarsi ⁴



Affiliations

• PMID: 32502524
• PMCID: PMC7264941
• DOI: 10.1016/j.ijantimicag.2020.106043

Free PMC article

Abstract

Novel coronavirus (COVID-19) pneumonia as a pandemic disease leads to acute respiratory distress syndrome (ARDS), acute cardiac injury, multi organ failure, and shock. In the absence of specific treatment for COVID-19, there is an urgent need to find the alternative treatments to manage this pandemic. Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia. It appears that imbalances between inflammatory and anti-inflammatory cytokines are the probable underlying mechanism. Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary. Here, we reported a challenging case of COVID-19 who was successfully treated with tocilizumab.

Keywords: Acute respiratory distress Syndrome; COVID-19; Coronavirus; Interleukin-6, Tocilizumab.